Who are BPM31510 Nanosuspension Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Copanlisib (BAY 80-6946), Haporine-S, 1PC002, Buparlisib & Paclitaxel, BAY86-5300, SHR0302.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bpm31510-nanosuspension-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BPM31510 Nanosuspension Injection — Competitive Intelligence Brief

BPM31510 Nanosuspension Injection (BPM31510 Nanosuspension Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K inhibitor. Area: Oncology.

phase 2 PI3K inhibitor PI3K (phosphatidylinositol 3-kinase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BPM31510 Nanosuspension Injection (BPM31510 Nanosuspension Injection) — BPGbio. BPM31510 is a nanosuspension formulation of buparlisib that inhibits phosphatidylinositol 3-kinase (PI3K) to block tumor cell proliferation and survival signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BPM31510 Nanosuspension Injection TARGET	BPM31510 Nanosuspension Injection	BPGbio	phase 2	PI3K inhibitor	PI3K (phosphatidylinositol 3-kinase)
Copanlisib (BAY 80-6946)	Copanlisib (BAY 80-6946)	Bayer	phase 3	PI3K inhibitor	PI3K (phosphatidylinositol 3-kinase), pan-class I
Haporine-S	Haporine-S	DH Bio Co., Ltd.	phase 3	PI3K inhibitor	PI3K
1PC002	1PC002	Orient Pharma Co., Ltd.	phase 3	PI3K inhibitor	PI3K
Buparlisib & Paclitaxel	Buparlisib & Paclitaxel	Adlai Nortye Biopharma Co., Ltd.	phase 3	PI3K inhibitor (buparlisib) + taxane chemotherapy (paclitaxel)	PI3K (buparlisib); β-tubulin (paclitaxel)
BAY86-5300	BAY86-5300	Bayer	phase 3	PI3K inhibitor	PI3K (phosphoinositide 3-kinase)
SHR0302	SHR0302	Jiangsu HengRui Medicine Co., Ltd.	phase 3	PI3K inhibitor	PI3K

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K inhibitor class)

Addpharma Inc. · 4 drugs in this class
AstraZeneca · 3 drugs in this class
Bayer · 3 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 drugs in this class
InventisBio Co., Ltd · 2 drugs in this class
Orient Pharma Co., Ltd. · 2 drugs in this class
Applied Biology, Inc. · 1 drug in this class
Angitia Incorporated Limited · 1 drug in this class
Aevi Genomic Medicine, LLC, a Cerecor company · 1 drug in this class
BPGbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BPM31510 Nanosuspension Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/bpm31510-nanosuspension-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab